IDH1 and glioma: Of note, gliomas with isocitrate dehydrogenase 1/2 (IDH1/2) mutations display significantly lower NRF2 levels as compared to their IDH1/2 wildtype diffuse glioma counterparts; however, in the subclass of IDH-mutant gliomas, high NRF2 levels were associated with a worse clinical prognosis [246,247].